logo
Underutilized workforce capacity may be costing CFOs millions

Underutilized workforce capacity may be costing CFOs millions

Yahoo2 days ago
This story was originally published on CFO.com. To receive daily news and insights, subscribe to our free daily CFO.com newsletter.
American businesses are losing millions in productivity each year, often with most CFOs not realizing it.
The analysis is from workforce productivity software provider ActivTrak's Workforce Utilization Benchmarks Report 2H 2025, which analyzed 5,619 organizations and 304,083 workers and found that companies operate at just 87% of expected productivity.
Across industries, this translates to the equivalent of 130 employees per 1,000 workers producing no output — or $11.2 million in wasted salary annually per 1,000 employees. For CFOs facing tight margins, talent shortages and pressure to optimize every dollar, the findings highlight how much value can be unlocked by keeping teams motivated and productive.
The hidden productivity gap and the state of work
ActivTrak CFO Jana Wilson told CFO.com the findings underscore a growing challenge not only for businesses operating in all types of work structures, but also for finance leaders trying to do more with smaller teams.
'Many finance teams are operating leaner than ever because of talent shortages, and automation can only fill so much of the gap,' Wilson said. 'Workforce utilization data shows leaders where they're getting the most out of their people and where capacity is being left on the table. That insight allows finance leaders to redeploy resources with precision instead of over-hiring or over-relying on technology without clear ROI.'
The report found that nearly six in 10 (58%) employees fail to meet daily productivity goals. For Wilson, that was the most alarming finding.
'CFOs tend to assume their teams are operating at full capacity because financial results often mask underlying inefficiencies,' she said. 'Our analysis shows there's significant untapped potential, particularly in back-office roles where contributions are harder to measure but critical to operations.'
Even small inefficiencies multiply at scale, according to the report: Organizations with 251 to 1,000 employees lose $1.3 million to $1.7 million annually, and enterprises with more than 1,000 employees see losses of $3.7 million to $3.9 million per year.
Industry comparisons reveal where the losses are concentrated. Computer hardware teams have nearly 71% of employees below productivity goals, the highest rate in the report. Aerospace organizations face the greatest untapped capacity at 19%, with average productivity losses of $1 million annually per company. On the other end, logistics organizations have the lowest rate of underperformance at 41% and the least untapped capacity at 9%.
'Workforce utilization data provides a place to start and helps leaders see how time is being spent and whether activity is aligned with company priorities,' Wilson said. Data also indicates that for finance leaders balancing lean teams and automation, the ability to pinpoint underutilization is key to avoiding common challenges in contemporary finance like poor hires or investments in technology that do not deliver ROI.
How CFOs can measure and respond
Wilson said CFOs should start with a simple approach to productivity measurement. 'Focus first on the work that directly ties to business outcomes — how much time is spent there versus low-value tasks? That alone can highlight where capacity might be misaligned,' she said.
She cautioned that capturing accurate workforce data is difficult for CFOs if they don't have proper systems designed for it. 'It's very difficult to collect this data or calculate productivity metrics consistently without a system built for it,' Wilson said.
'Workforce analytics tools make it easier to capture the right data objectively, but the real value comes from how you use it,' she added. 'Treat productivity metrics like financial metrics: Track them consistently, benchmark them and use them to drive action, not just as a reporting exercise.'
Wilson added that workforce insights can also support morale and engagement. 'Help people see how their work contributes to the bigger picture, especially in back-office roles that don't always have a direct line to revenue,' she said.
'Be transparent about the why behind decisions and use data to show teams how they're performing against benchmarks,' she said. 'That clarity builds trust and engagement. Finally, create space for feedback and recognition — when people feel heard and valued, they're more resilient during change.'
Recommended Reading
25% of workers 'very likely' to seek a new job
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

STERIS (NYSE:STE) Will Pay A Larger Dividend Than Last Year At $0.63
STERIS (NYSE:STE) Will Pay A Larger Dividend Than Last Year At $0.63

Yahoo

timea few seconds ago

  • Yahoo

STERIS (NYSE:STE) Will Pay A Larger Dividend Than Last Year At $0.63

STERIS plc's (NYSE:STE) periodic dividend will be increasing on the 26th of September to $0.63, with investors receiving 11% more than last year's $0.57. Despite this raise, the dividend yield of 1.0% is only a modest boost to shareholder returns. We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. STERIS' Payment Could Potentially Have Solid Earnings Coverage It would be nice for the yield to be higher, but we should also check if higher levels of dividend payment would be sustainable. Before making this announcement, STERIS was easily earning enough to cover the dividend. This means that most of what the business earns is being used to help it grow. Looking forward, earnings per share is forecast to rise by 59.3% over the next year. If the dividend continues on this path, the payout ratio could be 26% by next year, which we think can be pretty sustainable going forward. See our latest analysis for STERIS STERIS Has A Solid Track Record The company has a sustained record of paying dividends with very little fluctuation. Since 2015, the dividend has gone from $0.92 total annually to $2.28. This implies that the company grew its distributions at a yearly rate of about 9.5% over that duration. Companies like this can be very valuable over the long term, if the decent rate of growth can be maintained. We Could See STERIS' Dividend Growing The company's investors will be pleased to have been receiving dividend income for some time. We are encouraged to see that STERIS has grown earnings per share at 5.2% per year over the past five years. Growth in EPS bodes well for the dividend, as does the low payout ratio that the company is currently reporting. We Really Like STERIS' Dividend Overall, a dividend increase is always good, and we think that STERIS is a strong income stock thanks to its track record and growing earnings. Earnings are easily covering distributions, and the company is generating plenty of cash. Taking this all into consideration, this looks like it could be a good dividend opportunity. Market movements attest to how highly valued a consistent dividend policy is compared to one which is more unpredictable. At the same time, there are other factors our readers should be conscious of before pouring capital into a stock. As an example, we've identified 1 warning sign for STERIS that you should be aware of before investing. Looking for more high-yielding dividend ideas? Try our collection of strong dividend payers. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Earnings Release: Here's Why Analysts Cut Their Columbia Sportswear Company (NASDAQ:COLM) Price Target To US$57.50
Earnings Release: Here's Why Analysts Cut Their Columbia Sportswear Company (NASDAQ:COLM) Price Target To US$57.50

Yahoo

timea few seconds ago

  • Yahoo

Earnings Release: Here's Why Analysts Cut Their Columbia Sportswear Company (NASDAQ:COLM) Price Target To US$57.50

Columbia Sportswear Company (NASDAQ:COLM) just released its latest second-quarter results and things are looking bullish. Revenues beat expectations coming in atUS$605m, ahead of estimates by 2.9%. Statutory losses were somewhat smaller thanthe analysts expected, coming in at US$0.19 per share. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. With this in mind, we've gathered the latest statutory forecasts to see what the analysts are expecting for next year. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. Following last week's earnings report, Columbia Sportswear's nine analysts are forecasting 2025 revenues to be US$3.39b, approximately in line with the last 12 months. Statutory earnings per share are expected to decline 17% to US$3.40 in the same period. Yet prior to the latest earnings, the analysts had been anticipated revenues of US$3.40b and earnings per share (EPS) of US$3.48 in 2025. The analysts seem to have become a little more negative on the business after the latest results, given the minor downgrade to their earnings per share numbers for next year. See our latest analysis for Columbia Sportswear It might be a surprise to learn that the consensus price target fell 12% to US$57.50, with the analysts clearly linking lower forecast earnings to the performance of the stock price. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. There are some variant perceptions on Columbia Sportswear, with the most bullish analyst valuing it at US$79.00 and the most bearish at US$40.00 per share. Note the wide gap in analyst price targets? This implies to us that there is a fairly broad range of possible scenarios for the underlying business. Of course, another way to look at these forecasts is to place them into context against the industry itself. These estimates imply that revenue is expected to slow, with a forecast annualised decline of 1.6% by the end of 2025. This indicates a significant reduction from annual growth of 5.8% over the last five years. By contrast, our data suggests that other companies (with analyst coverage) in the same industry are forecast to see their revenue grow 5.6% annually for the foreseeable future. So although its revenues are forecast to shrink, this cloud does not come with a silver lining - Columbia Sportswear is expected to lag the wider industry. The Bottom Line The most important thing to take away is that the analysts downgraded their earnings per share estimates, showing that there has been a clear decline in sentiment following these results. Fortunately, the analysts also reconfirmed their revenue estimates, suggesting that it's tracking in line with expectations. Although our data does suggest that Columbia Sportswear's revenue is expected to perform worse than the wider industry. The consensus price target fell measurably, with the analysts seemingly not reassured by the latest results, leading to a lower estimate of Columbia Sportswear's future valuation. With that said, the long-term trajectory of the company's earnings is a lot more important than next year. We have estimates - from multiple Columbia Sportswear analysts - going out to 2027, and you can see them free on our platform here. You should always think about risks though. Case in point, we've spotted 2 warning signs for Columbia Sportswear you should be aware of, and 1 of them shouldn't be ignored. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

With 65% institutional ownership, Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) is a favorite amongst the big guns
With 65% institutional ownership, Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) is a favorite amongst the big guns

Yahoo

timea few seconds ago

  • Yahoo

With 65% institutional ownership, Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) is a favorite amongst the big guns

Key Insights Given the large stake in the stock by institutions, Rigel Pharmaceuticals' stock price might be vulnerable to their trading decisions 51% of the business is held by the top 9 shareholders Using data from analyst forecasts alongside ownership research, one can better assess the future performance of a company This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. To get a sense of who is truly in control of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL), it is important to understand the ownership structure of the business. With 65% stake, institutions possess the maximum shares in the company. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn). Given the vast amount of money and research capacities at their disposal, institutional ownership tends to carry a lot of weight, especially with individual investors. As a result, a sizeable amount of institutional money invested in a firm is generally viewed as a positive attribute. Let's take a closer look to see what the different types of shareholders can tell us about Rigel Pharmaceuticals. Check out our latest analysis for Rigel Pharmaceuticals What Does The Institutional Ownership Tell Us About Rigel Pharmaceuticals? Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index. We can see that Rigel Pharmaceuticals does have institutional investors; and they hold a good portion of the company's stock. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Rigel Pharmaceuticals' earnings history below. Of course, the future is what really matters. Since institutional investors own more than half the issued stock, the board will likely have to pay attention to their preferences. It would appear that 15% of Rigel Pharmaceuticals shares are controlled by hedge funds. That's interesting, because hedge funds can be quite active and activist. Many look for medium term catalysts that will drive the share price higher. Our data shows that BlackRock, Inc. is the largest shareholder with 9.7% of shares outstanding. Armistice Capital LLC is the second largest shareholder owning 8.5% of common stock, and Morgan Stanley, Investment Banking and Brokerage Investments holds about 8.3% of the company stock. Furthermore, CEO Raul Rodriguez is the owner of 0.8% of the company's shares. We did some more digging and found that 9 of the top shareholders account for roughly 51% of the register, implying that along with larger shareholders, there are a few smaller shareholders, thereby balancing out each others interests somewhat. While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future. Insider Ownership Of Rigel Pharmaceuticals While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO. Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group. Shareholders would probably be interested to learn that insiders own shares in Rigel Pharmaceuticals, Inc.. As individuals, the insiders collectively own US$5.5m worth of the US$392m company. Some would say this shows alignment of interests between shareholders and the board. But it might be worth checking if those insiders have been selling. General Public Ownership With a 19% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Rigel Pharmaceuticals. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders. Next Steps: It's always worth thinking about the different groups who own shares in a company. But to understand Rigel Pharmaceuticals better, we need to consider many other factors. For example, we've discovered 1 warning sign for Rigel Pharmaceuticals that you should be aware of before investing here. If you would prefer discover what analysts are predicting in terms of future growth, do not miss this free report on analyst forecasts. NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store